CLVS - Clovis Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.60
+0.40 (+7.69%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.20
Open5.46
Bid5.50 x 800
Ask5.68 x 2200
Day's Range5.45 - 5.85
52 Week Range4.98 - 37.27
Volume4,838,813
Avg. Volume2,737,571
Market Cap306.076M
Beta (3Y Monthly)1.67
PE Ratio (TTM)N/A
EPS (TTM)-7.49
Earnings DateOct 28, 2019 - Nov 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.00
Trade prices are not sourced from all markets
  • Benzinga

    AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis

    Last week, AstraZeneca plc (NYSE: AZN) reported positive results for its prostrate cancer treatment Lynparza for patients with certain genetic profiles. Ahmad wrote in a note on Tuesday that AstraZeneca’s incremental success changes the game for Clovis.

  • 3 Stocks That Are Absurdly Cheap Right Now
    Motley Fool

    3 Stocks That Are Absurdly Cheap Right Now

    Here are a few choice companies straight from the bargain bin.

  • Business Wire

    Clovis Oncology Announces Pricing of $250 Million of Convertible Senior Notes

    Clovis Oncology, Inc. (CLVS) announced today the pricing of $250 million aggregate principal amount of its 4.50% convertible senior notes due 2024 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Clovis Oncology has also granted to the initial purchasers a 13-day option to purchase up to $37.5 million aggregate principal amount of additional notes on the same terms and conditions. The holders of the notes may convert their notes at their option at any time prior to the close of business on the business day immediately preceding the maturity date at an initial conversion rate of 137.2213 shares of Clovis Oncology’s common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $7.29 per share of common stock.

  • Business Wire

    Clovis Oncology to Offer $225 Million of Convertible Senior Notes

    Clovis Oncology, Inc. (CLVS) announced today that, subject to market and other conditions, it intends to offer $225 million aggregate principal amount of its convertible senior notes due 2024 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Clovis Oncology also expects to grant the initial purchasers a 13-day option to purchase up to $33.75 million aggregate principal amount of additional notes on the same terms and conditions. Clovis Oncology will not have the right to redeem the notes prior to their maturity.

  • Thomson Reuters StreetEvents

    Edited Transcript of CLVS earnings conference call or presentation 1-Aug-19 12:30pm GMT

    Q2 2019 Clovis Oncology Inc Earnings Call

  • Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down
    Zacks

    Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down

    Clovis (CLVS) reports dismal second-quarter 2019 results. The company provides lower-than-expected guidance for product sales in 2019.

  • Clovis Oncology (CLVS) Q2 2019 Earnings Call Transcript
    Motley Fool

    Clovis Oncology (CLVS) Q2 2019 Earnings Call Transcript

    CLVS earnings call for the period ending June 30, 2019.

  • Here's Why Clovis Oncology Stock Fell as Much as 15.6% Today
    Motley Fool

    Here's Why Clovis Oncology Stock Fell as Much as 15.6% Today

    The company reported a net loss of $120 million for the second quarter, which was much worse than analysts expected.

  • Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
    Zacks

    Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know

    Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • What's in the Cards for Zynerba (ZYNE) This Earnings Season?
    Zacks

    What's in the Cards for Zynerba (ZYNE) This Earnings Season?

    Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be on the higher side in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.

  • Business Wire

    Clovis Oncology to Announce Second Quarter 2019 Financial Results and Host Webcast Conference Call on August 1

    Clovis Oncology, Inc. will announce its second quarter 2019 financial results on Thursday, August 1, 2019, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m.

  • Glaxo's Zejula Meets Goal in First-Line Ovarian Cancer Study
    Zacks

    Glaxo's Zejula Meets Goal in First-Line Ovarian Cancer Study

    Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer meets the primary endpoint.

  • Does Clovis Oncology, Inc. (NASDAQ:CLVS) Have A Particularly Volatile Share Price?
    Simply Wall St.

    Does Clovis Oncology, Inc. (NASDAQ:CLVS) Have A Particularly Volatile Share Price?

    Anyone researching Clovis Oncology, Inc. (NASDAQ:CLVS) might want to consider the historical volatility of the share...

  • Do Options Traders Know Something About Clovis (CLVS) Stock We Don't?
    Zacks

    Do Options Traders Know Something About Clovis (CLVS) Stock We Don't?

    Investors need to pay close attention to Clovis (CLVS) stock based on the movements in the options market lately.

  • Pfizer's Talzenna Gets Approval in Europe for Breast Cancer
    Zacks

    Pfizer's Talzenna Gets Approval in Europe for Breast Cancer

    Pfizer's (PFE) PARP inhibitor, Talzenna, receives approval in Europe for treating BRCA-mutated locally advanced or metastatic breast cancer.

  • AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use
    Zacks

    AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use

    AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.

  • Markit

    See what the IHS Markit Score report has to say about Clovis Oncology Inc.

    Clovis Oncology Inc NASDAQ/NGS:CLVSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for CLVS with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on June 14. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding CLVS are favorable, with net inflows of $2.40 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Is Clovis Oncology Inc (CLVS) A Good Stock To Buy?
    Insider Monkey

    Is Clovis Oncology Inc (CLVS) A Good Stock To Buy?

    Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the […]

  • Benzinga

    The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 6) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: ...

  • Business Wire

    Clovis Oncology Names Ginger L. Graham as New Board of Directors Chair

    “I am very pleased to announce that Ginger Graham is assuming the role of our Board Chair at Clovis Oncology. As an active Clovis board member for six years, Ginger is extremely familiar with our organization and will bring her tremendous expertise as a healthcare executive to her elevated role as Board Chair,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology.

  • Why Is Clovis (CLVS) Down 25.3% Since Last Earnings Report?
    Zacks

    Why Is Clovis (CLVS) Down 25.3% Since Last Earnings Report?

    Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Business Wire

    Expanded Rubraca® (Rucaparib) Data from Clovis Oncology’s ARIEL3 and TRITON2 Trials in Ovarian and Prostate Cancers to be Presented at 2019 ASCO Annual Meeting

    BOULDER, Colo.-- -- In exploratory analysis of ARIEL3 data, Rubraca significantly improved clinically meaningful endpoints including chemotherapy free interval and PFS on next therapy line for women with advanced ovarian cancer in maintenance treatment setting Updated Rubraca safety profile was consistent with the safety profile previously observed in ARIEL3 TRITON2 findings show that tumor tissue ...